For Treatment of Viral Hepatitis
Clinical trials of a novel drug Myrcludex B for treatment of chronic viral hepatitis B and D are ongoing.
Myrcludex B was developed in cooperation with biotechnological company Hepatera LLC (resident of biomedical technologies cluster at Skolkovo) and biotechnological company MYR, GmbH (a portfolio company of Maxwell Biotech Fund). Myrcludex B is a peptide synthesized equivalent to surface hepatitis B virus protein. It inhibits hepatitis B and D virus penetration into hepatic cells, interrupting viral life cycle and helping control the disease.
Phase one of studies have already been completed. Initiation of second phase 2 clinical trial of Myrcludex B has been announced to asses effectiveness and safety of the new drug. Clinical studies of Myrcludex B are supported by a grant of Skolkovo. It is suggested that 60 patients at 10 study sites in Russia will participate in the study.
Preliminary results may be available in 2018. The future of the new drug will largely depend on their results.